Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: InterMune | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: InterMune

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InterMune

2Q Revenues: $24.1 million (-10%)

2Q Loss: $44 million* (loss of $23.7 million in 2Q2005)

YTD Revenues: $48.5 million (-12%)

YTD Loss: $56.8 million (loss of 41.1 million YTD2005)

Comments: Revenues for the quarter were comprised solely of Actimmune sales. 2Q2005 revenues consisted of Actimmune and Aralast sales. The company stopped co-promoting Aralast in December 2005. R&D expense for quarter was $24.8 million, up 38%

*Results for the quarter include a $30 million reserve related to a proposed settlement with the government regarding promotional activities for Actimmune.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters